{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43(13)"],"submitter":["Banning AP"],"funding":["Volcano Corporation and Boston Scientific","European Cardiovascular Research Institute","National Institue for Health Research Biomedical Research Centre, Oxford"],"pubmed_abstract":["Aims
The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial.Methods and results
SYNTAX II was a multicentre, single-arm, open-label study of patients requiring revascularization who demonstrated clinical equipoise for treatment with either coronary artery bypass grafting (CAB"],"journal":["European heart journal"],"pagination":["1307-1316"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8970987"],"repository":["biostudies-literature"],"pubmed_title":["Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study."],"pmcid":["PMC8970987"],"pubmed_authors":["Ochala A","Ryan N","Onuma Y","Van Mieghem NM","Fath-Ordoubadi F","Cruz-Gonzalez I","Sabate M","Hildick-Smith D","Taggart D","Tijssen J","Hoole SP","Appleby C","Jan van Geuns R","Uren N","Zueco J","Farooq V","Piek JJ","Iniguez A","Spitzer E","Walsh S","Dudek D","Lesiak M","Buszman P","Escaned J","Zaman A","Moreno R","Serruys P","De Maria GL","Davies J","Banning AP","Gonzalo N","de Vries T","Goicolea J"],"additional_accession":[]},"is_claimable":false,"name":"Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.","description":"Aims
The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial.Methods and results
SYNTAX II was a multicentre, single-arm, open-label study of patients requiring revascularization who demonstrated clinical equipoise for treatment with either coronary artery bypass grafting (CAB","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-05T00:27:34.156Z","creation":"2024-10-18T03:20:29.454Z"},"accession":"S-EPMC8970987","cross_references":{"pubmed":["34617993"],"doi":["10.1093/eurheartj/ehab703"]}}